GlobeNewswire by notified

Q3 2023 results: A stable production quarter


Bíldudalur, 9th of November 2023

Icelandic Salmon is the parent company of Arnarlax, and other subsidiaries involved in salmon farming and processing in Iceland. The companies are collectively referred to as "Icelandic Salmon" or the "Group".


In the third quarter 2023, Icelandic salmon resumed harvesting, following a second quarter with limited harvest volume. The group harvested 4,040 tonnes in the quarter, up from 3,804 tonnes in the third quarter 2022.

“Our team demonstrated strong adaptability and commitment during a time with changing working conditions. Following a summer with limited harvest due to our focus on biological growth, we started harvesting in July. In the third quarter, total harvest came in slightly above the corresponding quarter last year, and the biological performance for the quarter was good” said Bjørn Hembre, CEO of Icelandic Salmon.

The group reported revenues of 42 million EUR in the third quarter 2023, up from 34 million EUR in the third quarter 2022. The EBIT for the quarter was positive of 3.0 million EUR, resulting in an EBIT/kg harvest of EUR 0.73. The EBIT/kg harvest was down from the corresponding quarter last year of EUR 0.99, due to higher costs, partly offset by strong price achievement compared to market prices.  

The smolt stocking continued in the third quarter and the group achieved operational improvements in smolt production. YTD the smolt weight is 236, up 36% from 2022.  

“The quality of the smolt is good and the survival rate of smolts is high. We see good effect of recent years’ investment and operational focus in our smolt production. “said Bjørn Hembre, CEO of Icelandic Salmon.

In October 2023, after the end of the third quarter, the group had to respond to an unfortunate biological challenge in Tálknafjörður. The incident was soon deemed a risk to animal health and the wellbeing of the fish, and a decision was made to take out significant volumes (see more information in Outlook below).

Strategic milestones

In September, Icelandic Salmon held its first Capital market day, giving stakeholders valuable insights into its operations and growth plans, and successfully completed a dual listing on the NASDAQ First North exchange in Iceland. This listing makes the company’s shares more easily accessible for Icelandic investors.

In August, Arnarlax signed a commitment letter for its first sustainability-linked loan agreement, totalling EUR 100 million, with DNB, Danske Bank and Arion Bank who stepped in with an overdraft facility and as security agent for the loan agreement.  The agreement was successfully completed in the beginning of November.


For the year 2023 as a whole, Icelandic Salmon expects to harvest 17,000 tonnes of salmon, up from the previous estimate of 16,000 tonnes. The increase is a result of growth beyond expected on our spring 2022 generation.

As mentioned above, Icelandic Salmon decided to take out significant volumes of fish in Tálknafjörður. This will have a one-off impact estimated at around EUR 5-6 million on profits in the fourth quarter 2023. Harvest volumes for 2024 is expected at 15,000 tonnes.

“For the longer term, we continue to see a potential for growth up to 26.000 tonnes on existing licenses supported by strong demand for sustainably farmed Atlantic Salmon,” said Bjørn Hembre, CEO of Icelandic Salmon.

The presentation9th of November

Attached is the presentation for the third quarter.

The presentation will be held at Arion Bank headquarters in Borgartún 19, 105 Reykjavík, in the conference room Þingvellir today, 9th of November. The conference room will be open from: 8:15 GMT (9:15 CEST) and company's CEO Bjørn Hembre and CFO Jónas Heiðar Birgisson will be presenting the company's results at 9:00 GMT (10:00 CEST), the presentation will also be available via webcast on

Questions may be asked after the presentation and there is also a possibility to send questions to during the presentation.

The presentation will be made available for replay on our website,, shortly after the live event.

For further information, please contact:

CEO Bjørn Hembre

Tel: +354 620 1936


CFO Jónas Heiðar Birgisson

Tel: +354 414 0609


About Icelandic Salmon: Icelandic Salmon is listed at the Euronext Growth. The company is the 100% owner of Arnarlax ehf, the leading farming company in Iceland with their head office in Bildudalur. The company is fully integrated, from egg to the fish is delivered to customers in the market, with control over all parts of the value chain.

See for more information about the company.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 202428.2.2024 07:00:00 CET | Press release

Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6th 2024 Ghent, Belgium – 28 February 2024– Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the late-breaking abstract including data from the RED DESERT and SAHARA proof-of-concept studies of the Company’s DSR therapy in patients with diuretic-resistant heart failure have been selected for a late-breaking presentation at THT 2024. Technology and Heart failure Therapeutics (THT) will be held from March 4th to 6th, 2024 in Boston, US and is an international conference on the latest heart failure innovations, focusing on device- and technology-based treatments within the context of drug therapies. The abstract “Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance” will be presented on Wednesday March 6th, 2024 by Dr. Jeffrey Testani, Associate Profe

12/2024・Trifork Holding AG – 2023 annual report and interim report for the quarter ending 31 December 202328.2.2024 07:00:00 CET | Press release

Trifork Holding AG Annual Financial Report Trifork Group – 2023 annual report and interim report for the quarter ending 31 December 2023 Company announcement no. 12 / 2024 Schindellegi, Switzerland – 28 February 2024 Trifork Group reports revenue growth of 12.4%for 2023 and 10.4% in Q4 2023 Full-year 2023 Trifork Group In 2023, Trifork Group revenue amounted to EURm 207.9, an increase of 12.4% from 2022. Organic growth was 9.3% driven by good activity in Digital Health, Smart Enterprise, Smart Building, and Cloud Operations. Inorganic growth of 3.1% came from the acquisitions of IBE and Chapter 5.Trifork Group EBITDA amounted to EURm 33.2, corresponding to 16.0% EBITDA margin.Trifork Group EBIT amounted to EURm 19.7, corresponding to 9.5% EBIT margin.Trifork Group net income amounted to EURm 17.4. Positive fair value adjustments in Trifork Labs of EURm 6.9 contributed to net income.Trifork Segment In 2023, adjusted EBITDA of the Trifork segment amounted to EURm 35.0, an increase of 9.7

Charlotte Hanneman to succeed Abhijit Bhattacharya as Philips’ Chief Financial Officer (CFO)28.2.2024 07:00:00 CET | Press release

February 28, 2024 Proposal to appoint Ms. Hanneman as member of Philips’ Board of Management fulfilling the role of CFO per October 1, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the proposal to appoint Charlotte Hanneman as member of the Board of Management, fulfilling the role of Chief Financial Officer (CFO), effective October 1, 2024. The proposal will be submitted to the Annual General Meeting of Shareholders (AGM), to be held on May 7, 2024. Ms. Hanneman will join Philips as a member of Philips’ Executive Committee on June 1, 2024, to start her induction and transition into the role, succeeding current CFO Abhijit Bhattacharya on October 1, 2024. Mr. Bhattacharya has been CFO and member of Philips’ Board of Management and Executive Committee since 2015 and will retire from the company after a successful 37-year career on September 30, 2024. Ms. Hanneman (Dutch, 1978) will join Philips with over 20 y

Idorsia and Viatris enter into a significant global research and development collaboration28.2.2024 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone payments, additional sales milestone payments and tiered royalties on annual net sales.Viatris and Idorsia will both contribute to the development costs for both programs.Includes future optionality to expand collaboration with additional pipeline assets.Combines Viatris’ financial strength and worldwide operational infrastructure with Idorsia’s proven, highly productive drug development team and innovative engine. Allschwil, Switzerland – February 28, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has entered into agreements for a significant global research and development collaboration with Viatris Inc. (NASDAQ: VTRS), a global healthcare company, for the global development and commercialization of tw

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 202328.2.2024 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operations with the termination of all of its employees, including Fabien de Ladonchamps, CEO, and notified SIX Swiss Exchange's listing authority that there was a substantial risk that it will lack the resources to have financial statements for 2023 prepared under IFRS audited, and that it is as a result likely not going to be able to satisfy the requirements for maintaining its listing on SIX. Fabien de Ladonchamps, CEO, will remain in function during the notice period for the duration of the moratorium process and beyond, as needed. On 29 January 2024, the Tribunal de première instance of Geneva granted a temporary moratorium (sursis provisoire) to ObsEva for a period of four months ending 29 May 2024 and appointed a commissioner (commi

HiddenA line styled icon from Orion Icon Library.Eye